Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine

Phase 4 Completed 20 enrolled Fogarty International Center of the National Institute of Health NIH Office of AIDS Research (OAR) · collab National Institute of Neurological Disorders and Stroke (NINDS) · collab National Institute on Minority Health and Health Disparities (NIMHD) · collab

Non-randomizedParallel-groupOpen-labelBasic science

Summary

A case control pharmacokinetic study evaluating the effects of atazanavir-ritonavir on the pharmacokinetics and toxicity of lumefantrine in people living with HIV attending APIN clinic of the Lagos University Teaching Hospital

Timeline

Start: 2018-09-18
Primary completion: 2019-05-15
Completion: 2019-08-15

Publications

Usman SO, Oreagba IA, Kadri MR, Adewumi OO, Akinyede A, Agbaje EO, Abideen G, Busari AA, Hassan OO, Akinleye MO, Akanmu AS. Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria. Eur J Clin Pharmacol. 2021 Sep;77(9):1341-1348. doi: 10.1007/s00228-021-03116-x. Epub 2021 Mar 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Artemether-lumefantrine	Unknown	80 mg	—
Subject	Artemether-lumefantrine	Unknown	480 mg	—
Subject	Atazanavir-ritonavir	Unknown	100 mg	—
Subject	Atazanavir-ritonavir	Unknown	300 mg	—

Indications

No indication recorded.